Literature DB >> 22665057

RhoD participates in the regulation of cell-cycle progression and centrosome duplication.

A Kyrkou1, M Soufi, R Bahtz, C Ferguson, M Bai, R G Parton, I Hoffmann, M Zerial, T Fotsis, C Murphy.   

Abstract

We have previously identified a Rho protein, RhoD, which localizes to the plasma membrane and the early endocytic compartment. Here, we show that a GTPase-deficient mutant of RhoD, RhoDG26V, causes hyperplasia and perturbed differentiation of the epidermis, when targeted to the skin of transgenic mice. In vitro, gain-of-function and loss-of-function approaches revealed that RhoD is involved in the regulation of G1/S-phase progression and causes overduplication of centrosomes. Centriole overduplication assays in aphidicolin-arrested p53-deficient U2OS cells, in which the cell and the centrosome cycles are uncoupled, revealed that the effects of RhoD and its mutants on centrosome duplication and cell cycle are independent. Enhancement of G1/S-phase progression was mediated via Diaph1, a novel effector of RhoD, which we have identified using a two-hybrid screen. These results indicate that RhoD participates in the regulation of cell-cycle progression and centrosome duplication.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665057     DOI: 10.1038/onc.2012.195

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  The RhoD to centrosomal duplication.

Authors:  Athena Kyrkou; Maria Soufi; Ramona Bahtz; Charles Ferguson; Maria Bai; Robert G Parton; Ingrid Hoffmann; Marino Zerial; Theodore Fotsis; Carol Murphy
Journal:  Small GTPases       Date:  2013-02-19

Review 2.  Fast-cycling Rho GTPases.

Authors:  Pontus Aspenström
Journal:  Small GTPases       Date:  2018-01-29

Review 3.  Formin' cellular structures: Physiological roles of Diaphanous (Dia) in actin dynamics.

Authors:  Sven Bogdan; Jörg Schultz; Jörg Grosshans
Journal:  Commun Integr Biol       Date:  2014-01-08

Review 4.  Structural Mechanisms and Drug Discovery Prospects of Rho GTPases.

Authors:  Cameron C Smithers; Michael Overduin
Journal:  Cells       Date:  2016-06-13       Impact factor: 6.600

Review 5.  Rho GTPases as therapeutic targets in cancer (Review).

Authors:  G A Cardama; N Gonzalez; J Maggio; P Lorenzano Menna; D E Gomez
Journal:  Int J Oncol       Date:  2017-08-09       Impact factor: 5.650

6.  RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6.

Authors:  Charlotte H Durkin; Flavia Leite; João V Cordeiro; Yutaka Handa; Yoshiki Arakawa; Ferran Valderrama; Michael Way
Journal:  Dev Cell       Date:  2017-05-08       Impact factor: 12.270

7.  Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis.

Authors:  Nabila Kazmi; Tim Robinson; Jie Zheng; Siddhartha Kar; Richard M Martin; Anne J Ridley
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.996

Review 8.  Rho GTPases modulate malignant transformation of tumor cells.

Authors:  Jose L Orgaz; Cecilia Herraiz; Victoria Sanz-Moreno
Journal:  Small GTPases       Date:  2014-05-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.